An Extension Study to Evaluate 24 Months of Standard-of-Care Osteoporosis Management Following Completion of 18 Months of BA058 (Abaloparatide) or Placebo Treatment in Protocol BA058-05-003
Phase of Trial: Phase III
Latest Information Update: 17 Mar 2018
At a glance
- Drugs Abaloparatide (Primary) ; Alendronic acid
- Indications Fracture; Postmenopausal osteoporosis
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms ACTIVExtend
- Sponsors Radius Health Inc.
- 17 Mar 2018 Results presented in a Radius Health media release.
- 17 Mar 2018 According to a Radius Health media release, results from this study were presented at the Endocrine Societys 100th Annual Meeting and Expo in Chicago.
- 12 Mar 2018 According to a Radius Health media release, clinical data from this study will be presented at ENDO 2018, the Endocrine Society's 100th Annual Meeting and Expo.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History